Financial Performance - In the first three quarters of 2025, the company achieved revenue of 841 million CNY, a year-on-year increase of 17.37% [2] - The net profit attributable to shareholders reached 89.81 million CNY, with a slight year-on-year growth of 0.26% [2] - For Q3 2025, revenue was 267 million CNY, showing a year-on-year growth of 2.24%, while net profit was 29.67 million CNY, remaining stable compared to the same period last year [2] Market Coverage - The company has established coverage in over 5,000 grade A medical institutions and penetrated more than 30,000 retail pharmacies and 20,000 grassroots medical units [3] - A network of over 650 commercial partners has been established across 30 provincial-level administrative regions, enhancing sales channels [3] Product Strategy - The company is focusing on the "Health China 2030" strategy, integrating R&D, production, and quality control to enhance product offerings [3] - A comprehensive marketing management system has been developed, employing a differentiated strategy for various products and markets [3] - The company is actively expanding its presence in the "Internet + Medicine" sector, leveraging digital marketing platforms and partnerships with major e-commerce platforms [3] Inventory Management - Channel inventory from commercial companies to hospitals is maintained at under one month, ensuring smooth turnover of core product inventories [4] Herbal Formula Granules - The herbal formula granules business is a key growth area, with 411 product varieties successfully registered and approved by the National Medical Products Administration [5] - The company is progressing with the listing of 111 products in nine provinces and is working on a second batch of 100 products [5] Research and Development - The company is advancing the development of the "Panlong Seven" gel patch, a strategic product for treating rheumatic bone diseases, which has recently received clinical approval [6] - The R&D pipeline includes other innovative drugs and chemical generics, with ongoing clinical trials for various products [6]

证券日报网讯 8月20日晚间，盘龙药业发布公告称，公司于近日收到国家药品监督管理局核准下发的盘 龙七凝胶贴膏注册临床试验的受理通知书。 （文章来源：证券日报） ...

盘龙药业公告，公司于近日收到国家药品监督管理局核准下发的盘龙七凝胶贴膏注册临床试验的受理通 知书。该产品为根据著名骨伤专家王家成老先生所献祖传秘方制成的独家品种盘龙七药酒基础上的中药 改良型创新药，功能主治为活血化瘀、祛风除湿、消肿止痛，适用于膝骨关节炎（气滞血瘀证）。药品 的前期研发以及产品从研制、临床试验报批到投产的周期长、环节多，容易受到一些不确定性因素的影 响，临床试验进程尚存在不确定性。 ...